Treatment responses with once-weekly teriparatide therapy for osteoporosis.

Shiraki M, Ueda S, Sugimoto T, Kuroda T, Nakamura T

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA27 May 2016Cited by 10 (Europe PMC)

PMID27234671PMCIDPMC5042992DOI10.1007/s00198-016-3640-5PepBankPUB-27234671

Read at source PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialEfficacy outcome
In osteoporosis, once-weekly teriparatide achieved lumbar BMD treatment success by LSC in 79.2% of subjects.
In plain wordsIn osteoporosis, 79.2% met the lumbar bone density success criterion during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableLumbar BMD treatment success by LSC
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
once-weekly · 72 weeksAs given in this study (human).
Measurements
Proportion with treatment success
79.2%
once-weekly teriparatide, 72 weeks; Lumbar BMD by LSC
Source sentences
Summary
Once-weekly teriparatide therapy for 72 weeks showed treatment success in 79.2 % of the subjects for lumbar BMD and 44.1 % for femoral neck BMD by LSC and in 50.5 and 39.6 % by absolute change, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The data of subjects whose lumbar or femoral neck bone mineral density (BMD) was measured in the TOWER study were included.
Summary · context
The least significant change (LSC) and the absolute change were used as the criteria for judgment of treatment success.
Report a problemFND-2723467101
02HumanNon-randomized trialEfficacy outcome
In osteoporosis, once-weekly teriparatide achieved femoral neck BMD treatment success by LSC in 44.1% of subjects.
In plain wordsIn osteoporosis, 44.1% met the femoral neck bone density success criterion during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableFemoral neck BMD treatment success by LSC
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
once-weekly · 72 weeksAs given in this study (human).
Measurements
Proportion with treatment success
44.1%
once-weekly teriparatide, 72 weeks; Femoral neck BMD by LSC
Source sentences
Summary
Once-weekly teriparatide therapy for 72 weeks showed treatment success in 79.2 % of the subjects for lumbar BMD and 44.1 % for femoral neck BMD by LSC and in 50.5 and 39.6 % by absolute change, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The data of subjects whose lumbar or femoral neck bone mineral density (BMD) was measured in the TOWER study were included.
Summary · context
The least significant change (LSC) and the absolute change were used as the criteria for judgment of treatment success.
Report a problemFND-2723467102
03HumanNon-randomized trialEfficacy outcome
In osteoporosis, once-weekly teriparatide achieved lumbar BMD treatment success by absolute change in 50.5% of subjects.
In plain wordsIn osteoporosis, 50.5% met the absolute lumbar bone density success criterion during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableLumbar BMD treatment success by absolute change
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
once-weekly · 72 weeksAs given in this study (human).
Measurements
Proportion with treatment success
50.5%
once-weekly teriparatide, 72 weeks; Lumbar BMD by absolute change
Source sentences
Summary
Once-weekly teriparatide therapy for 72 weeks showed treatment success in 79.2 % of the subjects for lumbar BMD and 44.1 % for femoral neck BMD by LSC and in 50.5 and 39.6 % by absolute change, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The data of subjects whose lumbar or femoral neck bone mineral density (BMD) was measured in the TOWER study were included.
Summary · context
The least significant change (LSC) and the absolute change were used as the criteria for judgment of treatment success.
Report a problemFND-2723467103
04HumanNon-randomized trialEfficacy outcome
In osteoporosis, once-weekly teriparatide achieved femoral neck BMD treatment success by absolute change in 39.6% of subjects.
In plain wordsIn osteoporosis, 39.6% met the absolute femoral neck bone density success criterion during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableFemoral neck BMD treatment success by absolute change
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
once-weekly · 72 weeksAs given in this study (human).
Measurements
Proportion with treatment success
39.6%
once-weekly teriparatide, 72 weeks; Femoral neck BMD by absolute change
Source sentences
Summary
Once-weekly teriparatide therapy for 72 weeks showed treatment success in 79.2 % of the subjects for lumbar BMD and 44.1 % for femoral neck BMD by LSC and in 50.5 and 39.6 % by absolute change, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The data of subjects whose lumbar or femoral neck bone mineral density (BMD) was measured in the TOWER study were included.
Summary · context
The least significant change (LSC) and the absolute change were used as the criteria for judgment of treatment success.
Report a problemFND-2723467104

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.